IMMIX BIOPHARMA, INC. Operating Cash Flow
IMMIX BIOPHARMA, INC. (IMMX) reported Operating Cash Flow of -$21.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$11.74M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$9.83M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.03M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$5.91M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$23.93M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$14.60M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$11.37M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$7.41M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$21.56M 10-Q · filed 2026-08-07 | -$32.59M derived: sum of 3 quarters · filed 2026-08-07 | -$38.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$9.83M 10-Q · filed 2026-05-07 | -$20.86M derived: sum of 2 quarters · filed 2026-05-07 | -$26.76M derived: sum of 3 quarters · filed 2026-05-07 | -$32.07M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$11.03M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | -$16.94M derived: sum of 2 quarters · filed 2026-03-27 | -$22.25M derived: sum of 3 quarters · filed 2026-08-07 | -$23.93M 10-K/A · filed 2026-03-27 |
| 2025-09-30 | -$5.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$11.22M derived: sum of 2 quarters · filed 2026-08-07 | -$12.90M 10-Q · filed 2025-11-07 | -$14.38M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$5.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$6.99M 10-Q · filed 2026-08-07 | -$8.47M derived: sum of 3 quarters · filed 2026-08-07 | -$12.51M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$1.69M 10-Q · filed 2026-05-07 | -$3.16M derived: sum of 2 quarters · filed 2026-05-07 | -$7.20M derived: sum of 3 quarters · filed 2026-05-07 | -$12.45M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.48M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | -$5.51M derived: sum of 2 quarters · filed 2026-03-27 | -$10.77M derived: sum of 3 quarters · filed 2026-03-27 | -$14.60M 10-K/A · filed 2026-03-27 |
| 2024-09-30 | -$4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$9.29M derived: sum of 2 quarters · filed 2025-11-07 | -$13.12M 10-Q · filed 2025-11-07 | -$15.80M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$5.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$9.08M 10-Q · filed 2025-08-08 | -$11.76M derived: sum of 3 quarters · filed 2025-08-08 | -$14.85M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$3.83M 10-Q · filed 2025-05-08 | -$6.50M derived: sum of 2 quarters · filed 2025-05-08 | -$9.59M derived: sum of 3 quarters · filed 2025-05-08 | -$13.11M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$5.76M derived: sum of 2 quarters · filed 2025-03-25 | -$9.28M derived: sum of 3 quarters · filed 2025-03-25 | -$11.37M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$6.60M derived: sum of 2 quarters · filed 2024-11-12 | -$8.69M 10-Q · filed 2024-11-12 | -$12.60M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$3.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$5.61M 10-Q · filed 2024-08-12 | -$9.51M derived: sum of 3 quarters · filed 2024-08-12 | -$10.97M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$2.09M 10-Q · filed 2024-05-09 | -$6.00M derived: sum of 2 quarters · filed 2024-05-09 | -$7.46M derived: sum of 3 quarters · filed 2024-05-09 | -$8.01M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$5.37M derived: sum of 2 quarters · filed 2024-03-29 | -$5.91M derived: sum of 3 quarters · filed 2024-03-29 | -$7.41M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$2.01M derived: sum of 2 quarters · filed 2023-11-13 | -$3.50M 10-Q · filed 2023-11-13 | -$4.62M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$547.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$2.04M 10-Q · filed 2023-08-11 | -$3.16M derived: sum of 3 quarters · filed 2023-08-11 | -$3.21M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$1.49M 10-Q · filed 2023-05-12 | -$2.61M derived: sum of 2 quarters · filed 2023-05-12 | -$2.66M derived: sum of 3 quarters · filed 2023-05-12 | -$2.82M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$1.16M derived: sum of 2 quarters · filed 2023-03-27 | -$1.32M derived: sum of 3 quarters · filed 2023-03-27 | -$1.59M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$50.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$208.77K derived: sum of 2 quarters · filed 2022-11-09 | -$475.21K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$158.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$424.45K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | -$266.45K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | -$404.69K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |